Tiziana life sciences ltd (“tiziana” or “the company”) - updated interim results for the six months ended 30 june 2022

London, dec. 29, 2022 (globe newswire) -- tiziana life sciences ltd (“tiziana”, nasdaq: tlsa), a biotechnology company enabling breakthrough cns immunomodulation approaches to enhance the functionality of treg-based therapies, today announced its interim results for the six months ended 30 june 2022.

TLSA Ratings Summary

TLSA Quant Ranking